Darci Zblewski

1.0k total citations
27 papers, 522 citations indexed

About

Darci Zblewski is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Darci Zblewski has authored 27 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 19 papers in Genetics and 5 papers in Immunology. Recurrent topics in Darci Zblewski's work include Acute Myeloid Leukemia Research (22 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Darci Zblewski is often cited by papers focused on Acute Myeloid Leukemia Research (22 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Darci Zblewski collaborates with scholars based in United States, Switzerland and Canada. Darci Zblewski's co-authors include Ayalew Tefferi, Mrinal M. Patnaik, Animesh Pardanani, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Naseema Gangat, Kebede H. Begna, Emnet A Wassie and Rebecca R. Laborde and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Darci Zblewski

26 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Darci Zblewski United States 10 321 289 232 85 80 27 522
Karen Lambie Canada 10 237 0.7× 121 0.4× 160 0.7× 47 0.6× 37 0.5× 12 406
J H Ohyashiki Japan 12 205 0.6× 98 0.3× 199 0.9× 191 2.2× 11 0.1× 24 457
Monika J. Stankiewicz United States 7 171 0.5× 90 0.3× 171 0.7× 48 0.6× 56 0.7× 11 336
Michela Rondoni Italy 13 390 1.2× 230 0.8× 123 0.5× 9 0.1× 156 1.9× 42 541
AM Gewirtz United States 12 383 1.2× 155 0.5× 103 0.4× 29 0.3× 17 0.2× 24 500
Akif Selim Yavuz Türkiye 10 161 0.5× 159 0.6× 119 0.5× 69 0.8× 287 3.6× 34 647
Kim-Hien T. Dao United States 10 303 0.9× 190 0.7× 309 1.3× 13 0.2× 80 1.0× 13 566
Chozha Vendan Rathinam United States 8 328 1.0× 112 0.4× 279 1.2× 17 0.2× 17 0.2× 16 646
Sonja Schindela Germany 13 620 1.9× 314 1.1× 368 1.6× 24 0.3× 34 0.4× 25 830

Countries citing papers authored by Darci Zblewski

Since Specialization
Citations

This map shows the geographic impact of Darci Zblewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darci Zblewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darci Zblewski more than expected).

Fields of papers citing papers by Darci Zblewski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darci Zblewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darci Zblewski. The network helps show where Darci Zblewski may publish in the future.

Co-authorship network of co-authors of Darci Zblewski

This figure shows the co-authorship network connecting the top 25 collaborators of Darci Zblewski. A scholar is included among the top collaborators of Darci Zblewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darci Zblewski. Darci Zblewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Begna, Kebede H., Naseema Gangat, Michelle A. Elliott, et al.. (2021). Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal. 11(3). 46–46. 8 indexed citations
2.
Ruan, Gordon, Courtney N. Day, William S. Harmsen, et al.. (2020). A population-based study of chronic neutrophilic leukemia in the United States. Blood Cancer Journal. 10(6). 68–68. 10 indexed citations
3.
Alkhateeb, Hassan B., Mrinal M. Patnaik, Aref Al‐Kali, et al.. (2020). Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. Anticancer Research. 40(7). 3883–3888. 1 indexed citations
4.
Patnaik, Mrinal M., David A. Sallman, Abhishek A. Mangaonkar, et al.. (2020). Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 136(7). 909–913. 31 indexed citations
5.
Vallapureddy, Rangit, Terra L. Lasho, Christy M. Finke, et al.. (2019). Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. American Journal of Hematology. 94(7). 767–779. 49 indexed citations
6.
Patnaik, Mrinal M., David A. Sallman, Abhishek A. Mangaonkar, et al.. (2019). A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML). Blood. 134(Supplement_1). 4234–4234. 3 indexed citations
7.
Al‐Kali, Aref, Darci Zblewski, James M. Foran, et al.. (2019). Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. Mayo Clinic Proceedings. 94(8). 1467–1474. 10 indexed citations
8.
Saadeh, Salwa, Darci Zblewski, Naseema Gangat, et al.. (2018). Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Annals of Hematology. 98(2). 331–337. 6 indexed citations
9.
Begna, Kebede H., Naseema Gangat, Michelle A. Elliott, et al.. (2018). A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3‐ITD mutational status. American Journal of Hematology. 93(12). E401–E404. 3 indexed citations
10.
Williams, Stephanie, Darci Zblewski, Michelle A. Elliott, et al.. (2016). Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease. Blood. 128(22). 2799–2799. 3 indexed citations
11.
Zblewski, Darci, Mrinal M. Patnaik, Kebede H. Begna, et al.. (2016). Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. Leukemia Research. 50. 112–115. 5 indexed citations
12.
Tefferi, Ayalew, Terra L. Lasho, Kebede H. Begna, et al.. (2015). A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. New England Journal of Medicine. 373(10). 908–919. 252 indexed citations
13.
Hefazi, Mehrdad, Mustaqeem Siddiqui, Mrinal M. Patnaik, et al.. (2015). Prognostic impact of combined NPM1+/FLT3− genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leukemia Research. 39(11). 1207–1213. 6 indexed citations
14.
Lasho, Terra L., Christy M. Finke, Darci Zblewski, et al.. (2015). Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. Blood Cancer Journal. 5(1). e275–e275. 38 indexed citations
15.
Pardanani, Animesh, Kaaren K. Reichard, Darci Zblewski, et al.. (2015). CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value. Leukemia. 30(4). 914–918. 21 indexed citations
16.
Pardanani, Animesh, Terra L. Lasho, Christy M. Finke, et al.. (2015). ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. British Journal of Haematology. 175(3). 534–536. 23 indexed citations
17.
Tefferi, Ayalew, Betsy LaPlant, Kebede H. Begna, et al.. (2014). Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study. Blood. 124(21). 634–634. 6 indexed citations
18.
Lasho, Terra L., Christy M. Finke, Teresa K. Kimlinger, et al.. (2014). Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms. Blood. 124(21). 5577–5577. 18 indexed citations
19.
Baidoun, Firas, Dong Chen, Hassan B. Alkhateeb, et al.. (2014). Clinical Outcome of Patients Diagnosed with Myelodysplastic Syndrome-Unclassifiable (MDS-U): Single Center Experience. Blood. 124(21). 3264–3264. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen Lambie Breakdown of academic impact, for papers by J H Ohyashiki Breakdown of academic impact, for papers by Monika J. Stankiewicz Breakdown of academic impact, for papers by Michela Rondoni Breakdown of academic impact, for papers by AM Gewirtz Breakdown of academic impact, for papers by Akif Selim Yavuz Breakdown of academic impact, for papers by Kim-Hien T. Dao Breakdown of academic impact, for papers by Chozha Vendan Rathinam Breakdown of academic impact, for papers by Sonja Schindela
Rankless by CCL
2026